Skip to main content
Contact Us
Subscribe
E-Edition
75°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ipsen
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
January 27, 2023
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
January 20, 2023
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
January 09, 2023
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
December 23, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
December 08, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
November 09, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
October 27, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting
October 25, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
August 12, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
August 05, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
August 03, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic
August 01, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance
July 28, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission
June 29, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury
June 09, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
May 26, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer
May 03, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022
April 27, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Receives Positive CHMP Opinion for Cabometyx® in Radioactive Iodine-refractory Differentiated Thyroid Cancer
March 25, 2022
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Announces Investment in New State-of-the-Art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) Designed to Improve Patient Experience
March 16, 2022
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen: Cabometyx® in Combination With Opdivo® Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-Up in the Phase III CheckMate -9ER Trial
February 15, 2022
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Presents Strong Full-Year 2021 Results and Enters Into Exclusive Negotiations to Divest Its Consumer Healthcare Business
February 11, 2022
From
Ipsen
Via
Business Wire
Tickers
OTC
Health Canada Approves Ipsen’s Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva
January 24, 2022
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Nominates Karen Witts as New Independent Board Member
January 21, 2022
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Appoints Stewart Campbell Executive Vice President and President of North America
November 03, 2021
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Pledges Ambitious Action on Climate Change
October 27, 2021
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Delivers Strong Sales Growth for the First Nine Months and Improves Its Full-Year Guidance
October 21, 2021
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3
October 18, 2021
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen appoints Mari Scheiffele as EVP and President, Specialty Care International
October 11, 2021
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer
September 18, 2021
From
Ipsen
Via
Business Wire
Tickers
OTC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.